DK1663182T4 - Hurtigt opløsende formulering af cinacalcet HCI - Google Patents

Hurtigt opløsende formulering af cinacalcet HCI Download PDF

Info

Publication number
DK1663182T4
DK1663182T4 DK04781429.8T DK04781429T DK1663182T4 DK 1663182 T4 DK1663182 T4 DK 1663182T4 DK 04781429 T DK04781429 T DK 04781429T DK 1663182 T4 DK1663182 T4 DK 1663182T4
Authority
DK
Denmark
Prior art keywords
fast dissolving
cinacalcet hcl
dissolving formulation
formulation
cinacalcet
Prior art date
Application number
DK04781429.8T
Other languages
English (en)
Other versions
DK1663182T3 (da
Inventor
Francisco J Alvarez
Glen Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663182(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1663182T3 publication Critical patent/DK1663182T3/da
Publication of DK1663182T4 publication Critical patent/DK1663182T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04781429.8T 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet HCI DK1663182T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (2)

Publication Number Publication Date
DK1663182T3 DK1663182T3 (da) 2013-04-15
DK1663182T4 true DK1663182T4 (da) 2020-02-17

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
DK18175499.5T DK3395340T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175495.3T DK3395338T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK17185704.8T DK3260117T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
DK04781429.8T DK1663182T4 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet HCI
DK18175497.9T DK3395339T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK14163366.9T DK2821067T3 (da) 2003-09-12 2004-09-10 Hurtigopløsningsformulering af cinacalcet

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK18175499.5T DK3395340T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175495.3T DK3395338T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK17185704.8T DK3260117T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering, der omfatter cinacalcet-hcl

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK18175497.9T DK3395339T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK14163366.9T DK2821067T3 (da) 2003-09-12 2004-09-10 Hurtigopløsningsformulering af cinacalcet

Country Status (30)

Country Link
US (7) US7829595B2 (da)
EP (8) EP3395339B8 (da)
JP (3) JP5026077B2 (da)
KR (1) KR101332058B1 (da)
CN (1) CN1946382B (da)
AR (1) AR045637A1 (da)
AU (1) AU2004279318C1 (da)
BR (2) BRPI0414254B8 (da)
CA (1) CA2536487C (da)
CY (5) CY1119609T1 (da)
DE (1) DE19164145T1 (da)
DK (6) DK3395340T3 (da)
EA (1) EA013425B1 (da)
ES (7) ES2655435T3 (da)
HR (1) HRP20130114T4 (da)
HU (5) HUE044822T2 (da)
IL (1) IL173737A (da)
IS (1) IS3027B (da)
MX (1) MXPA06002616A (da)
MY (1) MY142046A (da)
NO (1) NO335739B1 (da)
NZ (1) NZ545498A (da)
PL (6) PL3395338T3 (da)
PT (6) PT1663182E (da)
SG (1) SG146608A1 (da)
SI (6) SI3395339T1 (da)
TR (4) TR201910447T4 (da)
TW (1) TWI344363B (da)
WO (1) WO2005034928A1 (da)
ZA (1) ZA200602710B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
JP4773436B2 (ja) * 2005-05-16 2011-09-14 テバ ファーマシューティカル インダストリーズ リミティド シナカルセト塩酸塩の調製方法
ES2334260T3 (es) * 2005-05-23 2010-03-08 Teva Pharmaceutical Industries Ltd. Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet.
MX2007000982A (es) * 2005-05-23 2007-04-16 Teva Pharma Clorhidrato de cinacalcet amorfo y preparacion del mismo.
KR101552033B1 (ko) 2005-05-26 2015-09-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약학 조성물
EP1937233B1 (en) * 2005-09-02 2013-01-09 Amgen Inc. Modulating intestinal fluid balance using calcimimetics
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
DE602007003067D1 (de) * 2006-04-27 2009-12-17 Teva Pharma Verfahren zur herstellung einer cinacalcetbase
BRPI0702872A2 (pt) * 2006-04-27 2011-03-15 Teva Pharmaceutical Ind Ltda processos para preparação de cinacalceto e de uma sal farmaceuticamente aceitável do mesmo
JP5563296B2 (ja) 2006-06-21 2014-07-30 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 二次性副甲状腺機能亢進症の治療及び予防方法
EP2069285A1 (en) * 2006-06-27 2009-06-17 Sandoz AG Amorphous form of cinacalcet
CA2662315A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calcium receptor-active compound
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
ES2757517T3 (es) 2007-04-25 2020-04-29 Opko Ireland Global Holdings Ltd Liberación controlada de 25-hidroxivitamina D
WO2009002427A2 (en) * 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2010071689A2 (en) * 2008-05-05 2010-06-24 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
ES2393067T3 (es) 2008-09-25 2012-12-18 Ratiopharm Gmbh Cinacalcet compactado
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
US8476442B2 (en) 2009-03-20 2013-07-02 Vertex Pharmaceutical Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
CA2762130A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
DK2642980T3 (da) * 2010-11-23 2020-06-22 Amgen Inc Pædiatrisk formulering
RU2013128981A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении чувствительных к кальцию рецепторов
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
JP2014500882A (ja) 2010-11-26 2014-01-16 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
EP2793925B1 (en) * 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013107503A1 (en) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
ES2547577T3 (es) * 2012-11-09 2015-10-07 K.H.S. Pharma Holding Gmbh Formulaciones de liberación inmediata de cinacalcet
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
AU2013366640B2 (en) * 2012-12-21 2018-09-06 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3013324A1 (en) * 2013-06-26 2016-05-04 Jubilant Generics Limited Disintegrant free composition of cinacalcet
EP3116487A1 (en) * 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
AU2017244984A1 (en) 2016-03-31 2018-11-01 Intercept Pharmaceuticals, Inc. Oral preparation having exceptional elutability
US11331283B2 (en) * 2017-08-16 2022-05-17 Unichem Laboratories Ltd Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
WO2019186516A1 (en) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
EP4110304A4 (en) * 2020-02-29 2024-06-05 Zevra Therapeutics, Inc. COMPOSITIONS COMPRISING METHYLPHENIDATE PRODRUGS, METHODS OF PREPARATION THEREOF AND METHODS OF USE
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
NZ226696A (en) 1987-11-02 1991-10-25 Merck & Co Inc Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt%
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
ZA899071B (en) 1988-11-30 1990-08-29 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
RU2147574C1 (ru) 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
AU3777093A (en) 1993-02-23 1994-09-14 Brigham And Women's Hospital Calcium receptor-active molecules
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
PL181304B1 (pl) * 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
DK0907631T3 (da) 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR100771092B1 (ko) 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
JP2002527414A (ja) 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
EP1133233B1 (en) * 1998-11-23 2004-09-08 Monsanto Technology LLC Highly concentrated aqueous glyphosate compositions
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
JP2003518061A (ja) * 1999-12-22 2003-06-03 ファルマシア コーポレイション シクロオキシゲナーゼ−２阻害剤の持続放出製剤
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
WO2002024230A1 (en) 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (da) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
DE60220049T2 (de) 2001-06-22 2007-08-30 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2003238670A1 (en) 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040082588A1 (en) 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
ATE520406T1 (de) 2004-08-23 2011-09-15 Teva Pharma Kristalline form des ibandronat-natriums
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2717906C (en) 2008-03-11 2022-07-05 Jamu Alford System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
EP1663182A1 (en) 2006-06-07
SI3260117T1 (sl) 2019-08-30
HUE035596T2 (en) 2018-05-28
ES2655435T3 (es) 2018-02-20
HRP20130114T1 (xx) 2013-03-31
SG146608A1 (en) 2008-10-30
TR201910180T4 (tr) 2019-07-22
NZ545498A (en) 2010-04-30
TR201909267T4 (tr) 2019-07-22
PL3395339T3 (pl) 2019-09-30
EP2821067A1 (en) 2015-01-07
JP5940120B2 (ja) 2016-06-29
EP3578175B1 (en) 2022-11-30
ES2734057T3 (es) 2019-12-04
EP2821067B1 (en) 2017-10-25
IS3027B (is) 2021-03-15
IL173737A0 (en) 2006-07-05
EP3260117B1 (en) 2019-04-17
JP5849015B2 (ja) 2016-01-27
ES2401769T5 (es) 2020-07-01
AU2004279318A1 (en) 2005-04-21
CY1121812T1 (el) 2020-07-31
NO20061640L (no) 2006-06-12
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
CY1122259T1 (el) 2020-11-25
ES2735216T3 (es) 2019-12-17
MY142046A (en) 2010-08-30
CN1946382A (zh) 2007-04-11
PT2821067T (pt) 2017-12-01
PL3260117T3 (pl) 2019-10-31
US20210052518A1 (en) 2021-02-25
AU2004279318C1 (en) 2020-06-25
TR201910177T4 (tr) 2019-08-21
US20180243238A1 (en) 2018-08-30
EP3395339B1 (en) 2019-04-17
JP2015007089A (ja) 2015-01-15
AU2004279318B2 (en) 2010-02-25
HUE044822T2 (hu) 2019-11-28
PL3395340T3 (pl) 2019-10-31
ES2735226T3 (es) 2019-12-17
SI3395339T1 (sl) 2019-08-30
CA2536487A1 (en) 2005-04-21
PT3395340T (pt) 2019-07-15
HUE045411T2 (hu) 2019-12-30
EP3395338A1 (en) 2018-10-31
PT3260117T (pt) 2019-07-04
PT3395339T (pt) 2019-07-15
BR122018013029B1 (pt) 2022-04-12
EP3395340B1 (en) 2019-04-17
NO335739B1 (no) 2015-02-02
EP3395339A1 (en) 2018-10-31
CY1121814T1 (el) 2020-07-31
PL1663182T3 (pl) 2013-06-28
IS8324A (is) 2006-02-23
US20050147669A1 (en) 2005-07-07
US7829595B2 (en) 2010-11-09
CN1946382B (zh) 2010-12-08
BRPI0414254B8 (pt) 2021-05-25
AR045637A1 (es) 2005-11-02
CA2536487C (en) 2011-10-25
BRPI0414254B1 (pt) 2021-03-02
CY1119609T1 (el) 2018-04-04
DK2821067T3 (da) 2017-12-04
US9375405B2 (en) 2016-06-28
CY1121820T1 (el) 2020-07-31
JP5026077B2 (ja) 2012-09-12
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
JP2007505108A (ja) 2007-03-08
JP2012197280A (ja) 2012-10-18
PT3395338T (pt) 2019-07-23
ZA200602710B (en) 2007-04-25
IL173737A (en) 2012-04-30
ES2812198T1 (es) 2021-03-16
SI1663182T2 (sl) 2020-02-28
DK3260117T3 (da) 2019-07-01
EA013425B1 (ru) 2010-04-30
PL3395338T3 (pl) 2019-10-31
DK3395340T3 (da) 2019-07-15
EP3395340B8 (en) 2019-12-11
EP3395338B1 (en) 2019-05-01
ES2737348T3 (es) 2020-01-13
TW200518743A (en) 2005-06-16
EP3395339B8 (en) 2019-12-11
US20110136915A1 (en) 2011-06-09
HUE044279T2 (hu) 2019-10-28
EP3395340A1 (en) 2018-10-31
DK1663182T3 (da) 2013-04-15
EP3260117A1 (en) 2017-12-27
SI3395338T1 (sl) 2019-08-30
DK3395338T3 (da) 2019-07-22
PT1663182E (pt) 2013-03-14
SI3395340T1 (sl) 2019-08-30
PL1663182T5 (pl) 2020-07-27
EA200600566A1 (ru) 2006-08-25
EP2316442A1 (en) 2011-05-04
BRPI0414254A (pt) 2006-11-07
SI2821067T1 (en) 2018-03-30
TWI344363B (en) 2011-07-01
SI1663182T1 (sl) 2013-05-31
EP3260117B8 (en) 2019-11-27
PL2821067T3 (pl) 2018-02-28
ES2401769T3 (es) 2013-04-24
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
US20190117592A1 (en) 2019-04-25
DK3395339T3 (da) 2019-07-22
KR20070017460A (ko) 2007-02-12
US20200222340A1 (en) 2020-07-16
TR201910447T4 (tr) 2019-08-21
DE19164145T1 (de) 2021-04-29
WO2005034928A1 (en) 2005-04-21
EP1663182B2 (en) 2019-11-20
US20160338975A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
DK1663182T4 (da) Hurtigt opløsende formulering af cinacalcet HCI
DK2172205T3 (da) Farmaceutisk formulering bestående af lanthan-forbindelser
DE60328524D1 (de) Schutzvorrichtung gegen embolie
ATE452121T1 (de) Casr-antagonist
DE60321190D1 (de) Knopf
DK1725123T3 (da) Fremstilling af ekspanderede madcrackers
DE602004017626D1 (de) Antistatische gegenstände aus schmelzeverarbeitbaren fluorpolymeren
ATE489359T1 (de) Amidoacetonitril-verbindungen gegen parasiten
ATE390532T1 (de) Hochwasserschutz
DK1668076T3 (da) Vinylidenchloridpolymersammensætning
DK1569892T3 (da) Kalcilytiske forbindelser
IS7924A (is) Setnar anilín afleiður
NO20060375L (no) Famasoytisk preparat
SE0302861L (sv) Komparator
DE50310425D1 (de) Projektionsperimeter
ITMI20030641A1 (it) Composizioni espandibili di fluoropolimeri
SE0400585D0 (sv) NNRTI Antivirals
ITBG20030020A1 (it) Dispositivo di aggancio
FI5931U1 (fi) Keskusyksikköteline